Astellas Pharma Global Development Inc.

Gastrointestinal cancers and pancreatic malignancies

Research activity centers on gastric cancer, gastroesophageal junction adenocarcinoma, metastatic pancreatic adenocarcinoma, and related advanced solid tumors, with emphasis on tumors defined by CLDN18.2 expression and HER2-negative disease.

  • Gastric adenocarcinoma
  • Gastroesophageal junction adenocarcinoma
  • CLDN18.2-positive tumors
  • Metastatic pancreatic adenocarcinoma

The portfolio also includes studies in locally advanced unresectable and metastatic upper gastrointestinal disease.

Hematologic malignancies

Clinical research includes acute myeloid leukemia with FLT3 mutation, including FLT3-ITD disease in newly diagnosed, relapsed, and refractory settings, as well as treatment approaches for patients not eligible for intensive induction therapy.

  • Acute myeloid leukemia
  • FLT3-mutated AML
  • Relapsed or refractory leukemia
  • Newly diagnosed AML

These studies extend to younger populations and to combinations with other cancer therapies.

Genitourinary cancers and prostate cancer

The sponsor funds work in prostate cancer, including metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, alongside studies in locally advanced and metastatic urothelial cancer.

  • Prostate cancer
  • Metastatic castration-resistant prostate cancer
  • Metastatic hormone-sensitive prostate cancer
  • Urothelial cancer

Additional interest is shown in androgen receptor pathway-related treatment settings and broader genitourinary oncology.

Renal, bladder, and ocular disorders

Non-oncology research includes anemia associated with chronic kidney disease, neurogenic detrusor overactivity, and geographic atrophy, reflecting activity across kidney, bladder, and retinal disease areas.

  • Chronic kidney disease-related anemia
  • Neurogenic detrusor overactivity
  • Geographic atrophy
  • Retinal degeneration

These programs span both adult and pediatric populations.

Allergy, vasomotor symptoms, and supportive care

The clinical portfolio also covers allergy to house dust mites, moderate to severe vasomotor symptoms, and hot flushes associated with endocrine therapy in hormone receptor-positive breast cancer.

  • House dust mite allergy
  • Vasomotor symptoms
  • Hot flushes
  • Breast cancer supportive care

Related studies include symptom management and quality-of-life concerns across oncology and non-oncology settings.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Portugal Romania Spain
  • Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

    Not recruiting

    3 1
    Investigated drugs:
    Czechia Denmark France Germany Hungary Italy +3
  • Study of Zolbetuximab Alone and with Drug Combination for Patients with Advanced Stomach or Gastroesophageal Junction Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    France Italy
  • Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

    Not recruiting

    1 1 1 1
    France Germany Italy Spain
  • Study of Gilteritinib and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Chemotherapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Germany
  • Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

    Not recruiting

    2 1 1 1
    France Ireland Italy Spain